FIG 1.

Proposed diagnostic and risk stratification algorithm for patients with suspected NAFLD. ¹HBV and HCV serological workup should be completed in the primary care setting, with subsequent workup tailored to the individual patient by hepatology. Note that NAFLD may coexist with other chronic liver diseases. ²Evidence‐based optimal follow‐up of patients with NAFLD has not been established. The EASL recommends monitoring low‐risk patients with NAFLD without worsening metabolic risk factors every 2 to 3 years. ³Biopsy should also be considered in patients with increasing number of metabolic diseases who are at high risk for steatohepatitis.